



### Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended March 31, 2025, on Tuesday, May 13, 2025. Management will host a webcast and conference call at 8:30 a.m. ET to provide a corporate and financial update.

<b>Title:</b>	Humacyte First Quarter 2025 Financial Results and Corporate Update
<b>Date:</b>	May 13, 2025
<b>Time:</b>	8:30 AM Eastern Time
<b>Conference Call Details:</b>	1-877-704-4453 (U.S. Investors Dial) 1-201-389-0920 (International Investors Dial) 13753487 (Conference ID)
<b>Call me™ Feature:</b>	<a href="#">Click Here</a>
<b>Webcast:</b>	<a href="#">Click Here</a>

The webcast should be accessible 15 minutes prior to the conference call's start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company's website for at least 30 days.

#### About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte's 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte's 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit [www.Humacyte.com](http://www.Humacyte.com).

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

#### Humacyte Investor Contact:

Joyce Albare  
LifeSci Advisors LLC  
+1-617-435-6602  
[jalbare@lifesciadvisors.com](mailto:jalbare@lifesciadvisors.com)  
[investors@humacyte.com](mailto:investors@humacyte.com)

#### Humacyte Media Contact:

Rich Luchette  
Precision Strategies  
+1-202-645-3924  
[rich@precisionstrategies.com](mailto:rich@precisionstrategies.com)  
[media@humacyte.com](mailto:media@humacyte.com)



Source: Humacyte, Inc